Vipin Kumar Chaturvedi
Co-Founder & Chief Scientific OfficerDr. Vipin Kumar Chaturvedi, Ph.D. is the Co-Founder of GRI Bio, Inc. (formerly known as Glycoregimmune, Inc.). since 2009 and also served as its Advisor. He serves as Chief Scientific Officer of GRI Bio, Inc. since April 2023. He has been a Consultant for Astra-Zeneca and Bayer Pharmaceuticals. Dr. Chaturvedi served as GRI Operations’ Chief Scientific Officer from 2009 to 2017 and from 2022 to April 2023. He held several academic appointments at La Jolla Institute for Allergy and Immunology and at UCLA. He has been trained at Harvard and California Institute of Technology. He provides his expertise in type II NKT cell biology, inflammation and animal models of autoimmunity. He served as a Director of GRI Bio, Inc. (formerly known as Glycoregimmune, Inc.). He was a Founding Member of Arkagen. Dr. Chaturvedi is a Member of the Torrey Pines Institute for Molecular Studies (TPIMS). Dr. Chaturvedi has served as a Professor of Medicine, Laboratory of Immune Regulation at the University of California, San Diego since April 2015. In 2015, Dr. Chaturvedi co-founded Simomics, UK, a simulation software company and served as a non-executive director from 2015 to July 2022. Dr. Chaturvedi obtained his undergraduate degree in biology from the Kanpur University, India, his masters in biochemistry, molecular biology and immunology from the Institute of Medical Education & Research, India and his Ph.D. in Biochemistry from the Indian Institute of Science, Bangalore, India.
Positions
- Company NameGRI Bio, Inc.Stock CodeGRIPositionCo-Founder & Chief Scientific OfficerColleagues
